点击图片查看原图
重组人FGF-19
附带条件
特技
人FGF-19是由FGF19基因编码的。FGF-19属于FGF-19亚家族，FGF-19有三个成员，21, 23个。FGFs通常被认为是旁分泌因子，它们在胚胎发育过程中在组织图案化和器官发生中起着重要作用。相比之下，FGF-19亚家族最近已被证明以内分泌方式发挥作用。该亚家族成员与肝素结合位点的结合能力差，这是配体-受体复合物形成的关键因素。β-Klotho已被鉴定为FGF-19，21, 23信号转导所需的共同因子。可明显增加配体受体亲和力。与大多数FGFs结合和激活一个以上的FGF受体，FGF19是FGFR4的特异性配体。在FGF-19转基因小鼠中，可以观察到降低肝脏甘油三酯、增加脂肪酸氧化、降低葡萄糖水平和改善胰岛素敏感性。
附带条件
该材料由Sangon生物技术公司提供，用于研究、实验室或进一步评估目的。不适合人类使用。
附带条件
物理外观无菌过滤白冻干（冻干）粉末。
纯度为95%以上，采用SDS-PAGE和HPLC分析。
来源大肠杆菌。
与标准相比，生物活性完全具有生物活性。用BALB/C3T3细胞进行细胞增殖试验测定的ED50小于150 ng/ml，对应于6.7×103 IU/mg的比活力。
用0.2μm过滤浓缩液在pH 7.4的PBS中进行冻干。
LaAl法测定内毒素低于1 EU /μg的rHuFGF-19。
我们建议在打开之前将这个小瓶简单地离心，以将内容物带到底部。在含0.1% BSA的无菌蒸馏水或含水缓冲液中重组，浓度为0.1-1.0mg/mL。原料溶液应分摊到工作等分试样中，并储存在小于20℃的温度下，应在适当的缓冲溶液中进一步稀释。
AAA序列MRPLAFSCDAG PHLFSCASFRG IVRGVSCVRCA IGVALVRTVA IKGVHRTVIL CMGADGKMQGLLQYYPREDCA
概述
Human FGF-19 is encoded by the FGF19 gene. FGF-19 belongs to the FGF-19 subfamily which has three members FGF-19, 21, 23. FGFs are classically considered to be paracrine factors and are known for their roles in tissue patterning and organogenesis during embryogenesis. By contrast, the FGF-19 subfamily has recently been shown to function in an endocrine manner. Members of this subfamily have poor ability of binding to heparin binding site which is a crucial factor in ligand-receptor complex formation. β-Klotho has been identified as co-factor required for FGF-19, 21, 23 signaling. It can obviously increase ligand-receptor affinity. Unlike most FGFs which bind to and activate more than one FGF receptor, FGF19 is a specific ligand for FGF R4. In FGF-19 transgenic mice, reducing liver triglycerides, increasing fatty acid oxidation, reducing glucose levels and improving insulin sensitivity can be observed.
使用说明
This material is offered by Sangon Biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.
技术规格
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Purity | > 95 % by SDS-PAGE and HPLC analyses. |
| Source | Escherichia coli. |
| Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 150 ng/ml, corresponding to a specific activity of > 6.7 × 103 IU/mg. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1 EU/μg of rHuFGF-19 as determined by LAL method. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| AA Sequence | MRPLAFSDAG PHVHYGWGDP IRLRHLYTSG PHGLSSCFLR IRADGVVDCA RGQSAHSLLE IKAVALRTVA IKGVHSVRYL CMGADGKMQG LLQYSEEDCA FEEEIRPDGY NVYRSEKHRL PVSLSSAKQR QLYKNRGFLP LSHFLPMLPM VPEEPEDLRG HLESDMFSSP LETDSMDPFG LVTGLEAVRS PSFEK |
